Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of three beta-blocker drugs—nebivolol, atenolol, and carvedilol. All three are prescription medications used primarily for cardiovascular conditions such as hypertension and heart failure. Nebivolol is a highly selective beta-1 adrenergic receptor blocker with additional nitric oxide–mediated vasodilatory effects. Atenolol is a selective beta-1 adrenergic receptor blocker that reduces heart rate and cardiac output. Carvedilol is a non-selective beta-blocker with additional alpha-1 blocking activity, providing both vasodilation and antioxidant properties. Each drug has unique pharmacological features but all act by antagonizing the effects of catecholamines (like adrenaline) on the heart, leading to reduced blood pressure and decreased cardiac workload[2][4][5][6][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on nebivolol + atenolol + carvedilol.